Diagnostic Imaging Equipment Regulatory Harmonisation
14th May 18
A Senate Report has recommended that the Australian Government place licensing requirements for the supply, ownership and operation of diagnostic imaging equipment on the agenda for consideration by the Council of Australian Governments (COAG).
Key Issues For The Dental Industry —
A Senate Inquiry into red-tape in the health system has accepted advice from the Australian Dental Industry Association (ADIA) concerning the different state / territory government licensing requirements that affect businesses which supply, own and operate diagnostic imaging equipment.
ADIA has been a long-term proponent for the introduction of nationally consistent legislation in this regard. In it’s submission to the Senate Committee, ADIA advised that inconsistencies make it difficult for the dental industry to furnish oral healthcare professionals across the country with equipment, and the compliance burden associated with it imposes costs on business. These costs are passed on to patients and governments in the form of increased diagnostic imaging costs.
The ADIA Chief Executive Officer, Troy Williams, appeared before a hearing of the Senate Committee held in parliament house in March 2018. This provided an opportunity for ADIA to provide Senators with the information needed to properly consider the matter.
In response to ADIA’s representations, the Senate Committee acknowledged that, with respect to diagnostic imaging equipment, there is a significant and ongoing concern for dental practitioners. The committee agrees that there is clear scope to reduce red-tape in the licensing of this equipment.
The Senate Committee therefore recommended that the Australian Government place licensing requirements for the supply, ownership and operation of diagnostic imaging equipment on the agenda for consideration by COAG.
ADIA has written to the Minister for Health, the Hon. Greg Hunt MP, and his state / territory counterparts asking that COAG consider the matter with urgency.
This most recent Senate Committee report follows an inquiry undertaken in late 2017 by the Senate that reviewed the availability and accessibility of diagnostic imaging equipment around Australia.
Member Engagement —
ADIA provides leadership, strategy, advocacy and support. Our members set our agenda, fund our activities and directly benefit from the results. With respect to the Association's work to support to reduce the red-tape associated with the manufacture and supply of dental products the team in the ADIA national office receive advice and guidance from members serving on the ADIA-PRPC Product Regulation Policy Committee.
Further Information —
To keep up to date with how ADIA is working with the Australian Government to reduce red-tape subscribe to the Twitter feed @AusDental or follow us on Facebook at www.facebook.com/dental.industry. Alternatively, you can contact the Association via email at firstname.lastname@example.org or by telephone on 1300 943 094.
Currency Of Information & Disclaimer —
This update was issued on 14 May 2018 and please note that changes in circumstances after the publication of material or information may impact upon its accuracy and also change regulatory compliance obligations. The statements, regulatory and technical information contained herein are believed to be accurate and are provided for information purposes only. Readers are responsible for assessing its relevance and verifying the accuracy of the content. To the fullest extent permitted by law, ADIA will not be liable for any loss, damage, cost or expense incurred in relation to or arising as a result of relying on the information presented here.
This publication is available for your use under a Creative Commons Attribution 3.0 Australia licence, with the exception of the ADIA logo, images and where stated.
* To access this file you will need to access you ADIA Member Plus account.
To retrive your login details email email@example.com
6th Mar 19
The Therapeutic Goods Administration (TGA) has released an update on Brexit and the implications for therapeutic goods in Australia under any of the possible agreements that could occur.
2nd Aug 19
Advertisers of medicines and medical devices sometimes promote on labels and in other advertising that their product is ‘natural’ or contains ‘natural’ ingredients.